drug
Carboplatin Pfizer
Marketedupdated 5mo agoby $PFE PFIZER INC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugcarboplatin6 co-mentions · 6 sources
- tagOncology6 co-mentions · 2 sources
- tagBreast Cancer4 co-mentions · 1 sources
- tagDrug Shortage3 co-mentions · 3 sources
- tagPulmonology2 co-mentions · 1 sources
- tagNSCLC2 co-mentions · 1 sources
- tagApproval2 co-mentions · 1 sources
- companyAccord Healthcare Inc1 co-mentions · 1 sources
all catalysts(2)
Trials studying Carboplatin Pfizer
- phase2Two Part (Phase1b/ Phase3) Trial of Subcutaneous Dostarlimab Plus Carboplatin-Paclitaxel in Participants With Primary Advanced or Recurrent Endometrial Cancer
- phase1A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer
- phase2A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- phase3A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- phase3A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- phase2Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
- phase2Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
- phase3Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 1, 2045
~18.5 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Apr 1, 2045formulationUS 12427104
- Apr 1, 2045formulationUS 12427104
- Apr 1, 2045formulationUS 12427104
News(5)
- Platinum-based chemotherapy in childhood causes mutations that age the liverPlatinum chemotherapy aged the liver cells of treated children, making them look more like adult liver cells and possibly raising the long-term risk of new tumorsstat · 26d ago
- Ultra-low doses could bring costly cancer treatments to more patients in poorer countriesLow-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.stat · 4mo ago
- Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line StrategiesAparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.onclive · 4mo ago
- Poll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.onclive · 5mo ago
- ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You GoBreast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.onclive · 5mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that